BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldman JD. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. J Clin Pharm Ther 2020;45 Suppl 1:61-72. [PMID: 32910492 DOI: 10.1111/jcpt.13226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Goldman JD. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. J Clin Pharm Ther 2020;45 Suppl 1:61-72. [PMID: 32910492 DOI: 10.1111/jcpt.13226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Patel D. An overview of the once-weekly GLP-1 receptor agonists from the pharmacist's perspective. J Clin Pharm Ther 2020;45 Suppl 1:3-6. [PMID: 32910491 DOI: 10.1111/jcpt.13227] [Cited by in F6Publishing: 1] [Reference Citation Analysis]